The effectiveness of adding modafinil drug on negative symptoms of schizophrenic patients
Phase 2
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20161228031626N6
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Patients diagnosed with schizophrenia based on DSM-5 criteria
Schizophrenic patients who have been treated with risperidone or olanzapine.
Exclusion Criteria
Taking typical antipsychotic and atypical antipsychotic drugs, except for risperidone and olanzapine, and antidepressants, sodium valproate, lithium, and benzodiazepines.
The presence of accompanying psychiatric disorders such as schizoaffective or other psychotic disorders, bipolar disorder, anxiety disorders such as panic disorder or obsessive-compulsive disorder, post-traumatic stress disorder, eating disorder
Dependence or abuse of substances, drugs or alcohol, acutely or in the past 12 months, except for nicotine
Allergy to Modafinil or any of the placebo ingredients
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method egative symptoms. Timepoint: Before and 4 weeks after the study. Method of measurement: Scale for Assessment of Negative Symptoms (SANS).
- Secondary Outcome Measures
Name Time Method